Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

about

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors Emerging use of everolimus in the treatment of neuroendocrine tumors.

P2860

Q37514029-D7045208-8AA9-4E0B-886D-4BBB2908F3DB Q38661603-D03069F3-DDE9-4528-96EB-0607FEA4CF99

P2860

Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

Item

http://www.wikidata.org/entity/Q38842250

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Everolimus in the treatment of ...... astroenteropancreatic systems.

@en

type

Item

label

Everolimus in the treatment of ...... astroenteropancreatic systems.

@en

prefLabel

Everolimus in the treatment of ...... astroenteropancreatic systems.

@en

P1476

Everolimus in the treatment of ...... gastroenteropancreatic systems

@en

P2093

Juan W Valle

http://www.w3.org/2001/XMLSchema#string

Wasat Mansoor

http://www.w3.org/2001/XMLSchema#string

P2860

Common mechanisms of PIKK regulation

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Immunopharmacology of rapamycin

Side effects of interferon-alpha therapy

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

P304

2561-2578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.16.23

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M G McNamara

N Flaum

P577

2016-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27412069

http://www.w3.org/2001/XMLSchema#string

Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

about

P2860

P2860

Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698